The present disclosure relates to nanoparticle formulations and methods of use for alpha connexin c-terminal peptides. Methods of making and methods of use, for example in the treatment of cancer, are also provided.

The present disclosure relates to nanoparticle formulations and methods of use for alpha connexin c-terminal peptides. Methods of making and methods of use, for example in the treatment of cancer, are also provided.

Compositions and methods for systemic delivery of at least one cargo in a vascular plant. Compositions may include at least one cargo delivery particle, having a core and a shell; and at least one cargo disposed on the shell. The core may include at least one micronutrient. The shell may include a coating material. The at least one cargo delivery particle may have a size of less than about 10 nanometers. Methods may include administering an effective amount of the compositions to a plant.

A pea-derived peptide with a muscle-building effect and a preparation method thereof, and a drug and use, are disclosed. A pea protein is subjected to enzymatic hydrolysis, and five polypeptides with muscle-building effect are obtained by separation as separate peptide fragments. In an in vitro aging skeletal muscle cell assay, changes are analyzed in a gene expression level of regulatory pathways related to skeletal muscle cell proliferation and differentiation, apoptosis and autophagy, and protein synthesis and degradation. In addition, animal experiments are conducted to study the muscle-building effect and a corresponding mechanism of the pea-derived peptide. This shows that the five polypeptide sequences have a significant muscle-building effect, usable as a polypeptide drug for the treatment of sarcopenia.

The present invention relates to the methods of solid-phase peptide synthesis or recombinant production of ginsentide or ginsentide-like peptides or salts thereof. Further provided are uses of the ginsentide or ginsentide-like peptides or salts thereof as α1-adrenergic receptor antagonists and vasorelaxants, nitric oxide-boosting agents, anti-thrombotic agents, anti-atherosclerotic agents, as protective agents against doxorubicin-induced cardiotoxicity, anti-ageing and adaptogenic agents, nutraceuticals, health supplements, or cosmetic ingredients.

The invention is a cosmetic or dermatological preparation and the use thereof, said preparation comprising a combination of a) glycoprotein 1, b) glycoprotein 2, ginseng extract and d) equisetum extract, to protect the skin against extrinsic skin aging.

The invention is a cosmetic or dermatological preparation and the use thereof, said preparation comprising a combination of a) glycoprotein 1, b) glycoprotein 2, ginseng extract and d) equisetum extract, to protect the skin against extrinsic skin aging.

The invention relates to medicines, and more particularly to an abortion medication and an administration thereof, where the abortion medication contains 40-60 mg/mL of a kidney bean lectin. The invention also provides another abortion medication, which contains 40-60 mg/mL of a kidney bean lectin, 40-50 mg/mL of an oligosaccharide and 6-9 mg/mL of NaCl. The two abortion medications provided herein are both capable of effectively terminating the pregnancy and are safe without toxic side effects. Moreover, these drugs can be reused several times. These abortion medications are administered intrauterinely, which enables the kidney bean lectin therein to show the best abortive effect, and the local administration of these drugs in the uterine cavity has relatively simple operation.

A method for encapsulating active ingredients in liposomes having an active ingredient solution encapsulated with a bilayer composed of two monomolecular layers of amphiphilic compounds comprises: (a) providing the active ingredient solution; (b) providing an emulsion by emulsifying the active ingredient solution in a first liquid in the presence of the amphiphilic compound; (c) providing a liquid phase; (d) contacting the emulsion with the liquid phase to form a phase boundary; and (e) centrifuging the emulsion and the liquid phase that are in contact with one another via the phase boundary, wherein, on passage of the phase boundary, the amphiphilic compound enriched there is added onto the monomolecular inner layer to form a monomolecular outer layer, in order to create the bilayer.
The first liquid of the emulsion is chosen such that the solubility of the amphiphilic compound in the first liquid is not more than 1×10.sup.−4 mol/l.

The inventors provide a composition comprising an antimicrobial polypeptide comprising Blad or an active variant thereof for use in a method of treatment of the human or animal body by therapy or prophylaxis, such as for use in a method of treating or preventing an infection in or on a subject by a microorganism. Also provided is the use of a composition comprising an antimicrobial polypeptide comprising Blad or an active variant thereof to kill, or inhibit the growth of, a microorganism that is pathogenic to a human or an animal at a site that is not on or in the human or animal body.